An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

Andrew J. Vickers, Cathee Till, Catherine M. Tangen, Hans Lilja, Ian M. Thompson

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). Methods To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. Results Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23% vs 19%), particularly for high-grade (41% vs 25%) and clinically significant (32% vs 22%) disease. These findings were robust to the method of calculating PSA velocity. Conclusions We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines.

Original languageEnglish (US)
Pages (from-to)462-469
Number of pages8
JournalJournal of the National Cancer Institute
Volume103
Issue number6
DOIs
StatePublished - Mar 16 2011

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Guidelines
Biopsy
Area Under Curve
Neoplasms
Neoplasm Grading
Early Detection of Cancer
Practice Guidelines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. / Vickers, Andrew J.; Till, Cathee; Tangen, Catherine M.; Lilja, Hans; Thompson, Ian M.

In: Journal of the National Cancer Institute, Vol. 103, No. 6, 16.03.2011, p. 462-469.

Research output: Contribution to journalArticle

Vickers, Andrew J. ; Till, Cathee ; Tangen, Catherine M. ; Lilja, Hans ; Thompson, Ian M. / An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. In: Journal of the National Cancer Institute. 2011 ; Vol. 103, No. 6. pp. 462-469.
@article{4d8a27a425914fcfbc89bcec20f000f0,
title = "An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection",
abstract = "Background The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). Methods To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. Results Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23{\%} vs 19{\%}), particularly for high-grade (41{\%} vs 25{\%}) and clinically significant (32{\%} vs 22{\%}) disease. These findings were robust to the method of calculating PSA velocity. Conclusions We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines.",
author = "Vickers, {Andrew J.} and Cathee Till and Tangen, {Catherine M.} and Hans Lilja and Thompson, {Ian M.}",
year = "2011",
month = "3",
day = "16",
doi = "10.1093/jnci/djr028",
language = "English (US)",
volume = "103",
pages = "462--469",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

AU - Vickers, Andrew J.

AU - Till, Cathee

AU - Tangen, Catherine M.

AU - Lilja, Hans

AU - Thompson, Ian M.

PY - 2011/3/16

Y1 - 2011/3/16

N2 - Background The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). Methods To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. Results Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23% vs 19%), particularly for high-grade (41% vs 25%) and clinically significant (32% vs 22%) disease. These findings were robust to the method of calculating PSA velocity. Conclusions We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines.

AB - Background The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). Methods To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. Results Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23% vs 19%), particularly for high-grade (41% vs 25%) and clinically significant (32% vs 22%) disease. These findings were robust to the method of calculating PSA velocity. Conclusions We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines.

UR - http://www.scopus.com/inward/record.url?scp=79952833310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952833310&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr028

DO - 10.1093/jnci/djr028

M3 - Article

VL - 103

SP - 462

EP - 469

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -